Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

581 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Kinetics of the hepatitis B core-related antigen and treatment responses in chronic hepatitis B patients treated with tenofovir alafenamide.
Itokawa N, Atsukawa M, Tsubota A, Ishikawa T, Toyoda H, Takaguchi K, Watanabe T, Ogawa C, Hiraoka A, Okubo H, Uojima H, Chuma M, Nozaki A, Kato K, Mikami S, Tani J, Morishita A, Tada T, Asano T, Senoh T, Oikawa T, Okubo T, Kumada T, Iwakiri K. Itokawa N, et al. Among authors: hiraoka a. Hepatol Res. 2024 Apr 29. doi: 10.1111/hepr.14052. Online ahead of print. Hepatol Res. 2024. PMID: 38685853
Amino acid imbalance in patients with chronic liver diseases.
Michitaka K, Hiraoka A, Kume M, Uehara T, Hidaka S, Ninomiya T, Hasebe A, Miyamoto Y, Ichiryu M, Tanihira T, Nakahara H, Ochi H, Tanabe A, Uesugi K, Tokumoto Y, Mashiba T, Abe M, Hiasa Y, Matsuura B, Onji M. Michitaka K, et al. Among authors: hiraoka a. Hepatol Res. 2010 Apr;40(4):393-8. doi: 10.1111/j.1872-034X.2009.00614.x. Epub 2010 Mar 4. Hepatol Res. 2010. PMID: 20236360
Is there a survival benefit in interventional radiology for hepatocellular carcinoma in patients with Child-Pugh C liver cirrhosis?: A multicenter study.
Hiraoka A, Kumada T, Michitaka K, Toyoda H, Tada T, Ishikawa T, Itobayashi E, Shimada N, Takaguchi K, Takizawa D, Tsuji K; Hiroaki Nagamatsu, on behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group. Hiraoka A, et al. Hepatol Res. 2016 May;46(6):521-8. doi: 10.1111/hepr.12583. Epub 2015 Oct 2. Hepatol Res. 2016. PMID: 26331402
Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma.
Hiraoka A, Kumada T, Michitaka K, Toyoda H, Tada T, Ueki H, Kaneto M, Aibiki T, Okudaira T, Kawakami T, Kawamura T, Yamago H, Suga Y, Miyamoto Y, Tomida H, Azemoto N, Mori K, Miyata H, Ninomiya T, Kawasaki H. Hiraoka A, et al. J Gastroenterol Hepatol. 2016 May;31(5):1031-6. doi: 10.1111/jgh.13250. J Gastroenterol Hepatol. 2016. PMID: 26647219
Muscle volume loss as a prognostic marker in hepatocellular carcinoma patients treated with sorafenib.
Hiraoka A, Hirooka M, Koizumi Y, Izumoto H, Ueki H, Kaneto M, Kitahata S, Aibiki T, Tomida H, Miyamoto Y, Yamago H, Suga Y, Iwasaki R, Mori K, Miyata H, Tsubouchi E, Kishida M, Ninomiya T, Abe M, Matsuura B, Kawasaki H, Hiasa Y, Michitaka K. Hiraoka A, et al. Hepatol Res. 2017 May;47(6):558-565. doi: 10.1111/hepr.12780. Epub 2016 Aug 30. Hepatol Res. 2017. PMID: 27480045
581 results